Business Information
The company's principal activity is to develop cancer therapeutics by applying technology in immunotherapy and organic chemistry. The company is focused on synthetic therapeutic vaccines and innovative strategies for immunotherapy of cancer. The products of the company include theratope vaccine for breast cancer, blp25 vaccine for lung cancer, autologous vaccine for lymphoma and liposomal interleukin-2, designed to boost the general immune system. The company has its operations in Canada, the United States, barbados and Europe. Contract research and development accounted for 85% of 2001 revenues; licensing revenue from collaborative agreement, 12% and licensing and royalties, 3%.
|
|
Name |
Title
|
Email
|
| Christopher Henney | Chmn. | Available | | Edward Taylor | VP - Finance, Administration, CFO | Available | | Gary Christianson | COO | Available | | Lynn Kirkpatrick | Chief Scientific Officer | Available | | Marilyn Olson | VP - Clinical, Regulatory Affairs | Available
|
|
|
Year |
Sales |
Net Income |
| 2006 | 3,873 | (35,174) | | 2005 | 3,755 | (15,264) | | 2004 | 7,424 | (9,669)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
